CSBR
Champions Oncology, Inc.
stockNASDAQ
champions oncology, inc. is engaged in the development of advanced technology solutions to personalize the development and use of oncology drugs. champions tumorgraft™ technology platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments, or tumorgrafts, in a manner that preserves the biological characteristics of the original human tumor. champions believes that these tumorgrafts, unlike cell line derived xenografts used in tradition testing, closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. the company offers personalized tumorgraft development, drug studies and genome sequencing as part of its personalized oncology solutions ("pos") whereby physicians can evaluate the effects of cancer drugs on their patients' tumorgrafts and understand the genetic make-up of their patient's tumor enabling them
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 4.83 | 2026-10-27 | -0.21% | 0.551 |
| 1M | 4.94 | 2026-10-02 | -2.43% | 0.932 |
| 3M | 5.76 | 2026-08-03 | -16.32% | 0.330 |
| 6M | 5.89 | 2026-05-04 | -18.17% | 0.185 |
| 1Y | 6.80 | 2025-11-03 | -29.12% | 0.325 |
| 2Y | 4.24 | 2024-11-04 | +13.68% | — |
| 5Y | 9.99 | 2021-11-03 | -51.75% | -0.102 |
Champions Oncology, Inc. (NASDAQ:CSBR) stock price today is $4.82, and today's volume is 5,902. CSBR is up 0.208% today. The 30 day average volume is 9,317. CSBR market cap is $67.09M with 13.92M shares outstanding.